Lung cancer is a relatively common malignant tumor of the respiratory system. Depending on the nature of the pathology, lung cancer is divided into adenocarcinoma, squamous lung cancer and a small percentage of adenosquamous lung cancer. The speed of development of lung cancer may be related to the early or late stage of lung cancer detection and the presence or absence of lymph node metastasis. If the adenocarcinoma is in situ, the development may not be too fast, and the survival rate is generally high in 5-10 years, but of course, if metastasis has already occurred in other parts of the lung when it is detected, the development may be faster. Therefore, it also depends on the size of the primary lung cancer lesion and whether there are metastases from other sites at the time of detection. Generally, there are slightly more treatment options available for lung adenocarcinoma compared to squamous lung cancer. Because lung adenocarcinoma can still be treated with targeted drug therapy if genetic testing suggests mutation. If targeted therapy is effective, it can significantly prolong the survival and control the progression of the disease.